Risk factors
TriSalus Life Sciences (TLSI) risk factors
Item 1A of every TriSalus Life Sciences, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
58 risks, 1 new, 17 dropped, 10 reworded since the prior year. TriSalus added contractual intellectual property disputes as a new risk factor while streamlining capital and general market risks.
Filed Mar 05, 2026 - FY2024 10-K risk factors
74 risks. TriSalus faces high concentration risk dependent on its TriNav device and significant net losses since inception. The company relies heavily on ongoing clinical trials and third-party manufacturing for its drug candidate nelitolimod. Extensive healthcare regulations and reimbursement dynamics heavily impact commercial prospects.
Filed Apr 15, 2025